The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Homatropine is an anticholinergic that inhibits activity of the muscarinic acetylcholine receptor with less potency than atropine. Abuse potential (monitor). Life-threatening respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback